Commit Biologics has completed a $60 million seed financing to advance its complement-powered immune engager pipeline toward clinical development. Ackermans & van Haaren led the final close, with participation from new investors AbbVie Ventures and M Ventures. Existing investors Bioqube Ventures, Korys and Novo Holdings also participated.
Programming The Complement System
Commit is developing bispecific complement engagers designed to direct the complement system against diseased cells.
The complement system is an important component of the immune response, but it has remained relatively underused as a therapeutic mechanism.
Commit’s lead candidate, COM002, is designed to eliminate targeted cells independently of T cells. The company plans to use the financing to move the program toward clinical testing and develop additional candidates from its platform.
Preclinical findings do not establish safety or effectiveness in people. COM002 will need to complete required studies and regulatory reviews before the company can evaluate its performance in clinical trials.
The funding will also help Commit expand the scientific, manufacturing and operating foundation required to develop a new class of immunotherapies.
KEY QUOTES:
Commit was founded on a simple idea: that complement, one of the most powerful parts of our immune system, could be deliberately directed against diseased cells. With this financing, we will take COM002, a first-in-class immune engager that works independently of T cells, into the clinic and build the foundation for complement-powered immune engagers to become a new pillar of immunotherapy.
Thomas L. F. Montgomery Andresen, CEO of Commit Biologics
Seeing our first development candidate backed by such a strong group of financial and strategic investors is a proud moment for the whole team.
Thomas L. F. Montgomery Andresen, CEO of Commit Biologics
Complement is among the immune system’s most potent effector mechanisms yet remains largely untapped in drug development. Commit has made it programmable in a standard antibody, creating a path to medicines with differentiated efficacy and safety profiles across indications.
Charlotte Kremers, Principal at M Ventures
We firmly believe that Commit’s novel drug platform has the potential to generate a new treatment paradigm in immunotherapy based on the highly compelling preclinical data in targeted cell depletion. Ackermans & van Haaren is proud to support the Commit team and lead this financing to realize the full potential of the BiCE platform.
Lenny Van Steenhuyse, Investment Manager at Ackermans & van Haaren

